Peer-reviewed veterinary case report
Cytotoxic chemotherapy drug residues found in urine of dogs
By Knobloch, A et al.·Published in Journal of veterinary internal medicine·2010·Small Animal Hospital, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cytotoxic drug residues in urine of dogs receiving anticancer chemotherapy.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma or mast cell tumors undergoing chemotherapy had their urine tested for drug residues to see how long these substances lingered after treatment. The study found that different chemotherapy drugs, like cyclophosphamide, vincristine, vinblastine, and doxorubicin, were present in varying amounts right after treatment and for several days afterward. For example, cyclophosphamide was detectable immediately after treatment but dropped to undetectable levels within a few days. These findings are important for pet owners to understand potential exposure risks from their dogs' urine after chemotherapy.
People also search for: dog chemotherapy side effects · dog lymphoma treatment · how long are chemo drugs in dog urine
Abstract
BACKGROUND: The presence of cytotoxic drug residues in urine of dogs may represent an exposure risk for pet owners and other people as well as a potential environmental contaminant. However, studies on cytotoxic drug residues in excretions of clinical patients are lacking in veterinary oncology. HYPOTHESIS: Variable concentrations of cytotoxic residues are present in urine samples, depending on sampling time and substance. ANIMALS: Client-owned dogs with lymphoma or mast cell tumors treated with standard chemotherapy protocols. METHODS: Urine samples were collected before, directly after, and on days after administration of chemotherapy. Measurement of vincristine, vinblastine, cyclophosphamide, and doxorubicin residues in canine urine was performed by a quantitative liquid chromatography tandem mass spectrometry (LC/MS/MS) method. RESULTS: Median cyclophosphamide residue concentration was 398.2 microg/L directly after treatment (d0) and was below the level of detection on days 1-3 (d1, d2, d3). Median vincristine residue concentration was 53.8 microg/L directly after treatment and was 20.2, 11.4, and 6.6 microg/L on days 1, 2, and 3. Median vinblastine residues were 144.9 (d0), 70.8 (d1), 35.6 (d2), and 18.7 microg/L (d3) with low concentrations detectable for 7 days after treatment. Median urine doxorubicin concentrations were 354.0 (d0), 165.6 (d1), 156.9 (d2), and 158.2 microg/L (d3). Low concentrations of doxorubicin were measurable up to 21 days after administration. CONCLUSIONS AND CLINICAL IMPORTANCE: Variable concentrations of chemotherapeutics were measured in urine samples, depending on sampling time point and drug. Findings may inform current chemoprotection guidelines and help minimize exposure risks.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20102496/